Esketamine: How to Choose the Right Path for Treatment-Resistant Depression – Social Media Explorer

One of the most common points of confusion for patients exploring ketamine-based treatments is the relationship between intravenous ketamine infusion and esketamine nasal spray. Both involve ketamine-derived compounds, both work through the glutamate system, and both are used for treatment-resistant depression. But they are not the same treatment, and the differences between them are clinically meaningful in ways that affect which option is most appropriate for different patients.

Understanding these differences, and how a specialist psychiatric team approaches the choice between them, is increasingly relevant as both options have become more widely available in New York City.

The Pharmacological Relationship

Ketamine is a racemate, meaning it is a mixture of two mirror-image molecular forms known as enantiomers: the R-enantiomer and the S-enantiomer. Esketamine, the active ingredient in Spravato, is the pure S-enantiomer. The S-form binds more potently to the NMDA receptor than the R-form and is therefore effective at lower doses.

Intravenous ketamine infusion uses racemic ketamine, the mixture of both enantiomers, delivered directly into the bloodstream. Esketamine nasal spray uses only the S-enantiomer, delivered intranasally. Because of the different delivery routes, the pharmacokinetics differ: IV infusion produces more predictable blood levels and a faster onset of the dissociative experience, while intranasal delivery results in more variable absorption and a typically less intense acute experience.

Both produce antidepressant effects through the same primary mechanism. Both carry similar short-term safety considerations around dissociation, blood pressure changes, and sedation. The key differences lie in regulatory status, insurance coverage, clinical setting requirements, and the nature of the treatment experience.

Regulatory Status and Insurance Implications

This is perhaps the most practically significant difference for most patients. Esketamine nasal spray, sold as Spravato, is FDA-approved for treatment-resistant depression and for major depressive disorder with acute suicidal ideation. According to the FDA, Spravato must be used in conjunction with an oral antidepressant and administered under direct healthcare supervision in a certified facility. This regulatory approval means it has an established clinical evidence base, standardised dosing guidelines, and — critically — insurance coverage through most major commercial plans and Medicare and Medicaid for eligible patients.

Intravenous ketamine is not FDA-approved for psychiatric indications. Its use for depression is off-label, which means that the evidence base is substantial and widely accepted in clinical practice, but formal insurance coverage is much more limited. Most patients receiving IV ketamine do so on a self-pay basis, though some insurers do cover it in specific circumstances.

For patients who are cost-sensitive or who have insurance that covers Spravato but not IV ketamine, this distinction is decisive. For patients with the financial means to pursue either option or who have existing coverage for IV ketamine, the choice can be made on clinical grounds.

The Clinical Setting

Both treatments require administration in a supervised clinical setting and cannot be taken at home. The REMS requirements for Spravato mandate that it be administered in a certified healthcare facility with the capacity to monitor patients for at least two hours after each dose. IV ketamine infusion typically takes place in a clinical setting with continuous monitoring of vital signs throughout the infusion and a post-infusion observation period.

The clinical environments differ in some practical respects. A Spravato session involves the patient self-administering the nasal spray and then resting under observation; the procedure itself is straightforward. An IV infusion involves cannula insertion and continuous drip delivery over 40 to 60 minutes; the procedure is more medically intensive, though not significantly uncomfortable.

Village TMS esketamine services are delivered by their psychiatry-led team within a clinical environment designed to support patients through the treatment experience. Whether a patient is receiving IV ketamine or Spravato, the quality of the clinical oversight and the comfort of the environment are priorities that Village TMS takes seriously.

Making the Clinical Choice

For most patients, the choice between IV ketamine and esketamine nasal spray will be guided by a combination of clinical and practical factors that a specialist psychiatrist is best placed to weigh.

Patients who are good candidates for Spravato and whose insurance covers it will often start there, given the lower cost, the regulatory clarity, and the established insurance pathway. Patients who prefer the more controlled pharmacokinetics of IV delivery, who have not responded to Spravato, or whose clinical situation makes IV administration preferable may be better served by infusion.

The speed and intensity of effect can also be a clinical consideration. IV ketamine typically produces a more immediate and pronounced dissociative experience during administration, which some patients find distressing and others find therapeutically valuable. Esketamine’s intranasal delivery generally produces a milder experience, which may be preferable for patients who are more sensitive to dissociative effects.

For patients in New York City searching for ketamine infusion or IV ketamine treatment, Village TMS offers both options within a comprehensive psychiatric practice. Their team will conduct a thorough evaluation and provide honest, well-informed guidance about which treatment is most appropriate for your specific situation.

The Shared Goal

Regardless of which delivery method is used, the clinical objective of ketamine-based treatment is the same: to produce rapid, meaningful relief from depression in patients for whom conventional treatments have not been sufficient. The existence of two distinct delivery options — each with its own profile of advantages and limitations — gives clinicians and patients more flexibility in finding the approach that works best for any given individual.

Village TMS is ready to help you navigate these options. Contact their team today to schedule a comprehensive evaluation and begin a well-informed conversation about which ketamine-based treatment path is right for you.

The Role of the Treating Psychiatrist

Whichever form of ketamine-based treatment a patient pursues, the quality of the psychiatric oversight is the most important variable in the outcome. The decision about which treatment to use, the design of the protocol, the monitoring of response, and the integration of ketamine into the broader treatment plan all require genuine psychiatric expertise rather than simply the ability to administer the drug.

Village TMS delivers both IV ketamine infusion and Spravato within a fully integrated psychiatric practice, meaning that patients benefit from continuity of care between their ketamine treatment and any other psychiatric services they receive. If you are trying to understand which option is right for you, Village TMS offers comprehensive evaluations that clarify the choice. Contact their team today to begin the conversation.